Shilpa Pharma Lifesciences Limited, Unit-1, ANVISA Audit from Brazil

Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited, Unit-1 has successfully completed GMP inspection from Brazilian regulatory authority, ANVISA. The audit was carried out between June 30-July 4, 2025 and has been concluded with No Critical and No Major observations. Few other observations and recommendations were discussed during the inspection, which are procedural related.

Shilpa is committed to respond to the agency through appropriate CAPA plan on the other and recommendations points within the stipulated timelines.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 887.75 as compared to the previous close of Rs. 876.95. The total number of shares traded during the day was 2697 in over 217 trades.

The stock hit an intraday high of Rs. 896.00 and intraday low of 866.50. The net turnover during the day was Rs. 2381943.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 Pharmaceuticals ShilpaPharmaLifesciences Unit1 GMPInspection Brazil ANVISA